What this means
This trial plans to compare a fatty acid supplement with a placebo in 93 people. It has not started yet and has no results, so it cannot show whether the supplement helps.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 55 and over · 93 healthy adults aged 55 and older
- Where
- 1 site
The science
- Registered title
- Effect of Pentadecanoic Acid Supplementation on Red Blood Cell Health and Biological Aging in Healthy Older Adults
- Trial ID
- NCT07812792 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Red Blood Cell Health, Biological Aging, Healthy Aging
- What is tested
- Pentadecanoic Acid, Placebo
- Sponsor
- ReCellience15, Inc
- Ages
- 55 Years to no maximum
- Dates
- First posted Sep 10, 2026 · updated Oct 5, 2026
Registry summary
This Phase II randomized, double-blind, placebo-controlled, parallel-group study will evaluate the effects of pentadecanoic acid (C15:0) supplementation on red blood cell (RBC) health and predicted biological age in healthy adults aged 55 years and older. A total of 93 participants will be randomized to receive 200 mg of C15:0, 300 mg of C15:0, or placebo daily for approximately 12 weeks. The primary objective is to assess the effect of C15:0 on red blood cell distribution width (RDW-CV), a marker of RBC health, compared with placebo. Secondary outcomes include measures of inflammation, hematologic and iron metabolism markers, circulating C15:0 levels, biological age-related biomarkers, sleep quality, fatigue, energy, and health-related quality of life. Safety and tolerability will also be evaluated throughout the study.
Sites (1)
- Apex Trials, Guelph, Ontario - on, Canada